SEOM-TTCC clinical guideline in nasopharynx cancer (2021)
Por:
Dominguez, AR, Cirauqui, B, Castano, AG, Cabellos, RA, Maseda, AC, Fernandez, BC, Rey, LI, Rubio-Casadevall, J, Arrazubi, V and Mesia, R
Publicada:
1 abr 2022
Ahead of Print:
1 mar 2022
Resumen:
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.
Filiaciones:
Dominguez, AR:
Reg & Virgen de La Victoria Univ Hosp, Med Oncol Interctr Unit, IBIMA, Malaga 29010, Spain
:
Catalan Inst Oncol Badalona, Med Oncol Dept, B ARGO Grp, IGTP, Badalona, Spain
Castano, AG:
Hosp Marques de Valdecilla, Med Oncol Serv, Santander, Spain
Cabellos, RA:
Hosp Virgen de La Salud, Med Oncolgy Dept, Toledo, Spain
Maseda, AC:
Hosp Univ Lucus Augusti, Med Oncol Serv, Lugo, Spain
Fernandez, BC:
Hosp Univ La Paz, Med Oncol Dept, Madrid, Spain
Rey, LI:
Complejo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain
Rubio-Casadevall, J:
Hosp Josep Trueta, Med Oncol Dept, Catalan Inst Oncol, Girona, Spain
Arrazubi, V:
Complejo Hosp Navarra, Navarra Inst Hlth Res, Med Oncol Serv, IdiSNA, Pamplona, Spain
:
Catalan Inst Oncol Badalona, Med Oncol Dept, B ARGO Grp, IGTP, Badalona, Spain
Green Published, hybrid
|